EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges

Qinghuizi Luo, Wendi Jiang, Yiyang Xie, Zhe Dai, Jialong Zhu, Yuanyang Du, Xiaoyue Tao, Zengjie Lei, Xiaoyuan Chu, Bingji Wang, Gongbo Fu

Cancer Immunology, Immunotherapy · 27.01.2026 · 75 (2)

DOI: 10.1007/s00262-025-04274-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 27.01.2026. Verfasst von Qinghuizi Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, Key Program of Jiangsu Provincial Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-genetically modified adoptive cell therapies (ACTs) represent a rapidly advancing frontier in solid tumor immunotherapy, offering a safe and adaptable alternative to genetically engineered approaches by capitalizing on the intrinsic plasticity of immune cells. Genetic engineering strategies, including CAR-T cells, encounter significant obstacles in solid tumors, including on-target off-tumor toxicity, an immunosuppressive tumor microenvironment, and drug resistance. Although non-genetically modified ACTs-including tumor-infiltrating lymphocytes (TILs), cytokine-induced killer (CIK) cells, natural killer (NK) cells, and γδ T cells-offer unique advantages, their clinical application remains underexplored. This review consolidates the mechanistic basis, clinical progress, and limitations of non-genetically modified ACTs, proposing a paradigm shift toward combinatorial strategies. We systematically assessed how TILs overcome tumor microenvironment (TME) inhibition through lymphodepletion and cytokine assistance, compared the histocompatibility complex-unrestricted cytotoxicity of CIK cells with their functional diversity, and emphasized the innate flexibility of NK/γδ T cells against antigen-loss variants. By integrating preclinical and clinical data, we identify critical challenges: in vitro expansion inefficiency, absence of standardized protocols, and dynamic TME interactions. Furthermore, we advocated patient stratification by biomarkers, the addition of optimized cytokines, and rational combinations with checkpoint inhibitors or metabolic modulators to enhance efficacy. This review outlines the current landscape and proposes actionable solutions to reconcile the disparity between experimental potential and clinical applicability in non-genetically modified ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapy, AdoptiveHumansTumor MicroenvironmentAnimalsLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

Adoptive cell therapyNon-genetically modifiedSolid tumor treatmentTumor microenvironmentTumor-infiltrating lymphocytes

Autor:innen und Institutionen

  • Department of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of Oncology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. leizengjie@163.com.
  • Department of Oncology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. leizengjie@163.com.

Förderung

  • China Postdoctoral Science Foundation
  • Key Program of Jiangsu Provincial Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Luo, Q., Jiang, W., Xie, Y., Dai, Z., Zhu, J., Du, Y., Tao, X., Lei, Z., Chu, X., Wang, B., & Fu, G. (2026). Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. Cancer Immunology, Immunotherapy, 75(2). https://doi.org/10.1007/s00262-025-04274-y

Vancouver

Luo Q, Jiang W, Xie Y, Dai Z, Zhu J, Du Y, et al. Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. Cancer Immunology, Immunotherapy. 2026;75(2). doi:10.1007/s00262-025-04274-y

BibTeX
@article{Luo2026,
  author = {Luo, Qinghuizi and Jiang, Wendi and Xie, Yiyang and Dai, Zhe and Zhu, Jialong and Du, Yuanyang and Tao, Xiaoyue and Lei, Zengjie and Chu, Xiaoyuan and Wang, Bingji and Fu, Gongbo},
  title = {Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {2},
  doi = {10.1007/s00262-025-04274-y}
}
Kostenlos starten →